‌

US Patent 10835537 Combination therapies for treatment of cancer

Patent 10835537 was granted and assigned to Sumitomo Dainippon Pharma Oncology on November, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

Sumitomo Dainippon Pharma Oncology

Current Assignee

Sumitomo Dainippon Pharma Oncology

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

November 17, 2020

Patent Application Number

16821762

Date Filed

March 17, 2020

Patent Citations

US Patent 10422788 Profiling peptides and methods for sensitivity profiling

US Patent 10357488 Predicting response to alvocidib by mitochondrial profiling

US Patent 10562925 Alvocidib prodrugs having increased bioavailability

US Patent 10568887 Combination therapies for treatment of cancer

US Patent 10132797 Profiling peptides and methods for sensitivity profiling

US Patent 10259835 Alvocidib prodrugs having increased bioavailability

US Patent 10267787 Profiling peptides and methods for sensitivity profiling

Patent Citations Received

US Patent 12077554 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

0

US Patent 11530231 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

US Patent 11279694 Alvocidib prodrugs and their use as protein kinase inhibitors

US Patent 11497756 Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib

Patent Primary Examiner

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10835537 Combination therapies for treatment of cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.